目的 探讨经尿道前列腺等离子双极电切术(transurethral plasmakinetic resection of prostate,TUPKP)治疗高危良性前列腺增生(BPH)患者的临床疗效.方法 采用前瞻性多中心研究设计.在全国20家医院泌尿外科按照纳入排除标准,入组行TUPKP治疗的高危BPH患者,分析患者基线、围手术期及术后3个月随访的相关数据,评价疗效和安全性.结果 2016年9月至2018年12月共入组229名高危BPH患者.与基线相比,术后3个月随访的国际前列腺症状评分改变量为-17.28[95％CI(-18.02,-16.54)]分、最大尿流率改变量为 5.61[95％CI(0.68,10.54)]mL·s-1、残余尿量改变量为-84.50[95％CI(-96.49,-72.51)]mL、生活质量评分改变量为-3.24[95％CI(-3.42,-3.06)]分,差异均具有统计学意义(P＜0.05).术中及术后并发症的发生率低,未发生与手术相关的不良事件.结论 TUPKP可以用于治疗高危BPH患者,建议由技术熟练的术者实施手术.
Abstract
Objective To investigate the clinical efficacy of transurethral plasmakinetic resection of prostate(TUPKP)in treating high-risk benign prostatic hyperplasia(BPH)patients.Methods A prospective multicenter study design was employed.Patients with high-risk BPH treated with TUPKP were enrolled in the urology departments of 20 hospitals nationwide according to the inclusion and exclusion criteria.Relevant data regarding patient baseline,perioperative period,and 3-month postoperative follow-up were analyzed to evaluate efficacy and safety.Results From September 2016 to December 2018,a total of 229 high-risk BPH patients were enrolled.Compared to baseline at the 3-month follow-up,the change in the International Prostate Symptom Score was-17.28[95％CI(-18.02,-16.54)],the change in maximum urinary flow rate was 5.61[95％CI(0.68,10.54)]mL·s-1,the change in residual urine volume was-84.50[95％CI(-96.49,-72.51)]mL,and the change in quality of life score was-3.24[95％CI(-3.42,-3.06)],all showing significant differences(P＜0.05).The incidence of intraoperative and postoperative complications was low,and no surgery-related adverse events occurred.Conclusion TUPKP can be used to treat high-risk BPH patients,and it is recommended to be performed by skilled surgeons.
关键词
经尿道前列腺等离子双极电切术/良性前列腺增生/高危患者/心血管疾病
Key words
Transurethral plasmakinetic resection of prostate/Benign prostatic hyperplasia/High-risk patients/Cardiovascular diseases
维普
万方数据